![property](https://cn.mergerscorp.com/wp-content/uploads/2021/02/be66ec1c-4db5-4141-8d1f-bcddce99bac7-W768.jpg)
Global lower-middle market M&A Advisors
Countries in which we've closed transactions
Languages spoken by our Team
Total deals value
Global lower-middle market M&A Advisors
Countries in which we've closed transactions
Languages spoken by our Team
Total deals value
© 2024 MergersCorp M&A International.
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
该公司于 1982 年在印度旁遮普省成立,目的是生产活性药物成分。 该公司是一家活性药物成分 (API) 制造公司,为制药行业的几家领先公司生产原材料,这些公司使用这些产 ...
该公司于 1982 年在印度旁遮普省成立,目的是生产活性药物成分。
该公司是一家活性药物成分 (API) 制造公司,为制药行业的几家领先公司生产原材料,这些公司使用这些产品来制造药物。
他们为辉瑞、雅培、Cipla、Glenmark、Macleods、Aristo 等公司提供产品。
该公司提供的产品范围从抗生素、维生素、抗凝血剂到眼科产品。 印度和海外的监管机构也对业务进行了多个组织的审核,例如 ISO、ZED 和 GMP。
研究
企业正在研究重组蛋白的专利技术,该技术可用于新型靶向治疗,并确保无副作用。 目前,运营重点是高端新型分子。
研究
公司目前正在进行干细胞再生疗法的实验研究,这也有望成为未来没有任何副作用的药物。
生物技术
该公司在靶向人类治疗蛋白领域从事重要的生物技术研究活动。 其目前的研究工作重点是创造一种新药,在治疗哮喘和过敏患者的同时,还可以治疗肥大细胞增多症和嗜碱性白血病。
团队
团队由100名开明人士组成,包括化学家、药剂师、生物技术专家、质量控制人员、研发专家、仓储人员。
市场:65% 印度/35% 世界其他地区/欧洲
产品:25 种 OEM 产品/医药活性成分原材料
最畅销:抗生素
标准:ISO9001、欧盟标准(无 FDA)
增长率:20%+/年
规模: 100 多名员工
管理:化学工程师背景
财务: 收入 2500 万美元 / EBITDA 300 万美元
顾客:
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
This website is operated by MergersUS Inc a US Corporation with registered office at
Error: Contact form not found.
Error: Contact form not found.
Error: Contact form not found.
Error: Contact form not found.